&w=1200&resize=1200,675&ssl=1 "Indian pharmaceutical market registers 9.5% growth in March!
Achi-News")
Achi news desk-
The Indian Pharmaceutical Market (IPM) reported an increase of 9.5 percent in March. All treatments have made positive progress and the pharmaceutical market has confirmed that drugs are effective, with only respiratory therapy reporting slower growth. According to data from research firm Pharmarock, the market reported an increase of 0.7% across different therapeutic segments.
Advances in medicine
While most corporates have shown double-digit value growth, unit growth remains a challenge, said Sheetal Sapale, Vice President Commercial, Pharmarock.
Stating that the sales growth in March was mainly driven by value growth and new introductions, Sheetal said there was also growth in the anti-diabetic segment.
Also read:
Growing concern over human bone poisoning; The President declared a national emergency
Modification in many drugs
The iron supplement Orofer FCM lost its exclusivity on October 23, Sheetal said, citing the expiration of some patents and the loss of exclusivity rights in these segments by drug discovery companies in recent months. Therefore, there have been several launches of ferric carboxymaltose (FCM) products in the hematinic market.
Linagliptin, an oral antidiabetic drug introduced by Boehringer Ingelheim, went off patent last year, and Eli Lilly’s dulaglutide went off patent in February 2024.
A significant increase
In March, Alchem ​​was among the few companies to report positive unit growth and value growth. It had value growth of 15.1 per cent and unit growth of 11.3 per cent in March.
Other drugmakers such as Cadilla, Fortes and Natco Pharma also reported double-digit value and unit growth in March.
Which drugs have had how many jobs
Glaxo Smith Kline’s Augmentin and USV’s GP Glycomet retained their positions as the best-selling drug brands in March.
Augmentin achieved sales of Rs 73 crore in March. Both products faced unit growth challenges in March, but Augmentin reported 10 percent growth during the month.
Tulunada Puja for Tirupati Thimmappa!
Prescribed drugs
Condom brand Manforce Mankind retained third place in March, although the product reported unit and value growth in the negative range.
The brand has quoted sales of Rs 51 crore in March 2024. The respiratory segment of Cipla’s Forcort inhaler retained the fourth position with sales of Rs 50 crore in March.
Abbott’s weight management/type 2 diabetes drug Rybelsus showed a remarkable double-digit growth rate of 7 percent in March and a unit growth rate of 75 percent.
Read the latest news first at News 18 Kannada. Get daily fresh news, live news update on Believer News 18 in Kannada
&w=1200&resize=1200,0&ssl=1&description=Indian+pharmaceutical+market+registers+9.5%25+growth+in+March%21%0A%0A+Achi-News){kind=link}